Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowA federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
Evista is an osteoporosis drug that generated global sales of $1 billion last year, including $700
million in the United States.
U.S. District Court Judge Sarah Evans Barker ruled that Lilly’s method-of-use
patents for Evista are valid through 2014, rejecting all the claims of Israel-based Teva Pharmaceuticals Industries Ltd.
However, Barker said Lilly’s patents on Evista’s particle size are invalid. Lilly said it is considering
whether to appeal that part of the ruling.
Teva has sought to market a cheaper generic version of Evista, also
known as raloxifene.
Please enable JavaScript to view this content.